Radiation can cause pneumonitis, which is a form of lung injury. Pneumonitis can be caused by bacteria or viruses, but an irritant can cause it, similar to an allergic reaction. Radiation pneumonitis can develop after radiation treatment to the chest or lungs. Radiation treatment for lung cancer can cause pneumonitis in 5 to 15% of patients. Although it is most common to appear between 4-12 weeks after radiation treatment, it may occur as early as one week. It can also grow slowly over many months in other situations. The most common treatment for severe pneumonitis is a long-term course of corticosteroids such as prednisone. These powerful anti-inflammatory drugs work by suppressing the immune system to reduce inflammation in the lungs. A patient may need oxygen therapy to aid breathing during treatment. This depends on their symptoms.
Request a sample to get more information on the Radiation Pneumonitis Treatment market (Use Corporate email ID to Get Higher Priority): https://market.us/report/radiation-pneumonitis-treatment-market/request-sample/
Segmentation of the global radiation pneumonitis market can be done based on – End-User, Technology, Risk of Development, and Region. Below is a detailed segmental description.
Based on the Risk of Development:
• Patient-Related Factors
– Pre-Existing Lung Conditions
– Smoking Associated Hypoxia
• Treatment-Related Factors
– Radiation Therapy
Based on Technologies:
• Radiation Therapy
Based on End-User:
• Research Centers & Laboratories
• Research Institutions
Based on Region:
• North America
• South America
• Middle East & Africa
Market Dynamics –
The Global Radiation Pneumonitis Treatment Market Drivers:
Radiation pneumonitis treatment will be in high demand because of the increased risk of radiation pneumonitis from both patient-related and treatment-related factors. Radiation pneumonitis can be caused by patient-related factors such as gender, age, smoking status, performance, and underlying pulmonary conditions.
Radiation pneumonitis treatment has seen a rise in demand due to the development of new approaches to prevention and treatment.
Competitive Landscape –
The market’s key players are: Provision Healthcare LLC, Hitachi Ltd., Elekta AB, C. R. Bard Inc., Optivus Proton Therapy Inc., Mevion Medical Systems Inc., Panacea Medical Technologies Pvt. Ltd., Isoray Medical Inc., and Varian Medical Systems Inc., among others. These industry leaders are now focusing their efforts on mergers, partnerships and acquisitions, product development, collaboration strategies, and other ways to maintain their competitive edge.